Author

Ningning Ding

Observed names: Ding Ningning, N N Ding, N. Ding, Ning‐Ning Ding

Observed institutions: Xuzhou Medical College, Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center, BeiGene (China), Affiliated Hospital of Xuzhou Medical College, Cancer Hospital of Chinese Academy of Medical Sciences

ORCID: 0000-0002-3937-7302

Observed ORCID: 0000-0002-3937-7302

OpenAlex ID: A5003990860

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

2022 · Lin Shen, Ken Kato, et al. · Journal of Clinical Oncology · 331

PDF

Predictors of lymph node metastasis and possible selective lymph node dissection in clinical stage IA non-small cell lung cancer

2018 · Ningning Ding, Yousheng Mao, et al. · Journal of Thoracic Disease · 49

PDF

Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non–small-cell Lung Cancer: A Propensity Score Matching Study

2020 · Yue Zhao, Yousheng Mao, et al. · Clinical Lung Cancer · 39

[Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database].

2020 · Y S Mao, S G Gao, et al. · PubMed · 25

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial

2025 · Zhihao Lu, Wenting Du, et al. · Journal of Clinical Oncology · 24

Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life

2022 · E. Van Cutsem, K. Kato, et al. · ESMO Open · 24

PDF

Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy

2018 · Lin Yang, Yikun Yang, et al. · Journal of Thoracic Disease · 23

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein

2016 · Jiang Cao, Hao Feng, et al. · Cancer Medicine · 18

PDF

The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis

2018 · Feng Li, Ningning Ding, et al. · International Journal of Surgery · 15

Experiences in the management of anastomotic leakages and analysis of the factors affecting leakage healing in patients with esophagogastric junction cancer

2017 · Ningning Ding, Yousheng Mao, et al. · Journal of Thoracic Disease · 13

PDF

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma

2017 · Yikun Yang, Yousheng Mao, et al. · Journal of Thoracic Disease · 12

PDF

Correlation between CXCR4 , CXCR5 and CCR7 expression and survival outcomes in patients with clinical T1N0M0 non‐small cell lung cancer

2020 · Zhao Yue, Ding Ningning, et al. · Thoracic Cancer · 11

PDF

[Exploration of lymph node metastasis and appropriate lymph node dissection modes in patients with clinical stage I non-small cell lung cancer].

2014 · Zhirong Zhang, Yousheng Mao, et al. · PubMed · 8

Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients

2023 · Sung-Bae Kim, Eric Van Cutsem, et al. · Current Medical Research and Opinion · 5

[Advances in Lymph Node Metastasis and the Modes of Lymph Node Dissection in Early Stage Non-small Cell Lung Caner].

2016 · Ningning Ding, Yousheng Mao · PubMed Central · 5

PDF

Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302

2024 · Hiroki Hara, Taroh Satoh, et al. · Esophagus · 3

PDF

[Key technology of lymph node dissection along recurrent laryngeal nerve and its associated complication prevention in patients with thoracic esophageal cancer].

2019 · Y S Mao, J He, et al. · PubMed · 3

[Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].

2015 · Ying Liu, Xiaoling Chen, et al. · PubMed · 3

Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.

2022 · Kuaile Zhao, Sung-Bae Kim, et al. · Journal of Clinical Oncology · 2

O1-1 Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup

2022 · Hiroki Hara, Taroh Satoh, et al. · Annals of Oncology · 1

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).

2022 · Eric Van Cutsem, Ken Kato, et al. · Journal of Clinical Oncology · 1

Erratum: Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy

2019 · Lin Yang, Yikun Yang, et al. · Journal of Thoracic Disease · 1

PDF

Sjögren’s Syndrome Complicated by Myeloid/Natural Killer Cell Precursor Acute Leukemia: Case Report and Review of the Literature

2016 · Hao Feng, Jianlin Qiao, et al. · Case Reports in Hematology · 1

PDF

[Advances of mediastinal lymph node metastasis and the extent of lymph node dissection in patients with stage T1 non-small cell lung cancer].

2015 · Ningning Ding, Yousheng Mao · PubMed Central · 1

PDF

MO19-4 Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma

2023 · Ken Kato, Eric Van Cutsem, et al. · Annals of Oncology

PDF

Works count: 28

Citation count: 618

H-index: 11

I10-index: 12